Ikena Oncology grabs $120m Series B
Ikena Oncology Inc, a developer of patient-directed, biomarker-driven cancer therapies, has secured $120 million in Series B financing.
Ikena Oncology Inc, a developer of patient-directed, biomarker-driven cancer therapies, has secured $120 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination